MBRX News & Events

Moleculin Biotech entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,122,652 shares of common stock of the Company at an exercise price of $3.90 per share. The issuance or resale of the shares of common stock issuable upon exercise of the outstanding warrants has been registered pursuant to effective registration statements. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $8.3 million, before deducting financial advisory fees. Roth Capital Partners is acting as the Company's financial advisor for this transaction. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 6,367,956 shares of common stock, at an exercise price equal to the lesser of $3.90 per share or the lowest volume weighted average price of the Company's common stock on any trading day during the next five trading days, will be exercisable upon shareholder approval and for a term of five years from the date of shareholder approval. The transaction is expected to close on or about February 20, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Moleculin Biotech announced that the Japan Patent Office, JPO, has issued a notice of allowance for Patent Application No. 2021-577862 titled, "Method of reconstituting Liposomal Annamycin." A patent from the application is expected to be issued in the coming months. "Securing strong patent protection across key global markets remains a core strategic priority as we advance our non-cardiotoxic therapy for relapsed or refractory acute myeloid leukemia through pivotal Phase 3 development," commented Walter Klemp, Chairman and CEO of Moleculin. "This newly allowed Japanese patent further strengthens our international intellectual property position by protecting critical methods supporting the preparation and clinical use of our therapy, reinforcing our confidence in its long-term value as we work toward potential regulatory approval and commercialization in key territories worldwide."

Moleculin Biotech announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company's corporate developments, clinical progress and strategic initiatives. "Transparency and timely communication are central to building trust with our investors," commented Klemp. "Our CEO Corner gives us the opportunity to go beyond standard press releases, providing deeper context on our pipeline programs, clinical milestones and business strategy. We are focused on advancing our lead programs, including our ongoing clinical trials, and delivering long-term value for our shareholders."